{"title":"GLP-1 Research Peptides","description":"","products":[{"product_id":"tirzepatide-glp-1-gip-peptide-vial-5mg-lyophilisate","title":"Tirzepatide GLP-1\/GIP Peptide Vial Lyophilisate For Lab Research","description":"\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eBATCH NR: NBLTR107261101\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eTESTED FOR:\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003e✓\u003c\/span\u003e\u003c\/strong\u003e\u003cstrong\u003e\u003cspan\u003ePURITY\u003c\/span\u003e\u003c\/strong\u003e\u003cb\u003e\u003cspan\u003e\u003cbr\u003e\u003c\/span\u003e\u003c\/b\u003e\u003cstrong\u003e\u003cspan\u003e✓\u003c\/span\u003e\u003c\/strong\u003e\u003cstrong\u003e\u003cspan\u003eWEIGHT\u003c\/span\u003e\u003c\/strong\u003e\u003cb\u003e\u003cspan\u003e\u003cbr\u003e\u003c\/span\u003e\u003c\/b\u003e\u003cstrong\u003e\u003cspan\u003e✓\u003c\/span\u003e\u003c\/strong\u003e\u003cstrong\u003e\u003cspan\u003eENDOTOXINS(LPS)\u003c\/span\u003e\u003c\/strong\u003e\u003cb\u003e\u003cspan\u003e\u003c\/span\u003e\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan\u003eVIEW LAB REPORTS\u003cbr\u003e\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cdiv id=\"cell_20065285\"\u003e\n\u003cdiv data-draggable=\"true\" class=\"single-item other-item\"\u003e\n\u003cdiv class=\"ntb-datas-wrapper\"\u003e\u003cspan spellcheck=\"false\" id=\"mce_1\" class=\"hover-item mce-content-body\" data-placeholder=\"Add New\" data-v-bd450b80=\"\"\u003e\u003cstrong\u003e\u003cspan\u003eTIRZEPATIDE TEST RESULTS:\u003cbr\u003e\u003c\/span\u003eDate Tested: 01.07.2026\u003cbr\u003ePurity: 99,883%\u003cbr\u003eWeight: 9,83 mg\u003cbr\u003eEndotoxin (LPS): Pass\u003c\/strong\u003e\u003c\/span\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003chr\u003e\n\u003ch2\u003eOverview\u003c\/h2\u003e\n\u003cp\u003eTirzepatide is a synthetic peptide-based medication designed as a dual agonist of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.\u003c\/p\u003e\n\u003cp\u003eIn research and clinical contexts, tirzepatide is primarily studied for its effects on glucose regulation, insulin sensitivity, appetite signaling, and body weight modulation. It represents a newer class of incretin-based therapies that integrate two metabolic pathways into a single molecular framework.\u003c\/p\u003e\n\u003cp\u003eUnlike earlier GLP-1 receptor agonists, tirzepatide simultaneously targets both GLP-1 and GIP signaling systems, which are central to postprandial metabolic regulation.\u003c\/p\u003e\n\u003chr\u003e\n\u003ch2\u003eMechanism of Action\u003c\/h2\u003e\n\u003cp\u003eTirzepatide acts through dual incretin receptor activation:\u003c\/p\u003e\n\u003chr\u003e\n\u003ch3\u003e1. GLP-1 Receptor Activation\u003c\/h3\u003e\n\u003cp\u003e✓ Enhances glucose-dependent insulin secretion\u003cbr\u003e✓ Suppresses glucagon release during hyperglycemia\u003cbr\u003e✓ Slows gastric emptying (delayed nutrient absorption)\u003cbr\u003e✓ Promotes satiety signaling via central nervous system pathways\u003c\/p\u003e\n\u003chr\u003e\n\u003ch3\u003e2. GIP Receptor Activation\u003c\/h3\u003e\n\u003cp\u003e✓ Enhances insulin secretion in glucose-dependent manner\u003cbr\u003e✓ Modulates lipid metabolism and energy storage pathways\u003cbr\u003e✓ Influences adipose tissue function in metabolic models\u003cbr\u003e✓ Works synergistically with GLP-1 signaling to improve glycemic control\u003c\/p\u003e\n\u003chr\u003e\n\u003ch3\u003e3. Combined Dual Incretin Effect\u003c\/h3\u003e\n\u003cp\u003eWhen both pathways are activated simultaneously, research and clinical studies show:\u003c\/p\u003e\n\u003cp\u003e✓ Improved glycemic control compared to single-pathway agents\u003cbr\u003e✓ Enhanced appetite regulation and reduced caloric intake\u003cbr\u003e✓ Modulation of body weight and fat mass distribution\u003cbr\u003e✓ Improved metabolic efficiency in insulin-resistant states\u003c\/p\u003e\n\u003chr\u003e\n\u003ch2\u003eResearch and Clinical Applications\u003c\/h2\u003e\n\u003cp\u003eTirzepatide is studied extensively in metabolic medicine:\u003c\/p\u003e\n\u003chr\u003e\n\u003ch3\u003eType 2 Diabetes Research\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eGlycemic control improvement in insulin resistance models\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eHbA1c reduction mechanisms\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eBeta-cell function support in experimental and clinical studies\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr\u003e\n\u003ch3\u003eObesity and Body Weight Regulation\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eAppetite suppression and satiety signaling\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eReduction of adipose tissue mass\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eEnergy intake and expenditure balance studies\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eCentral nervous system appetite regulation pathways\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr\u003e\n\u003ch3\u003eCardiometabolic Research\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eLipid profile modulation\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eInsulin sensitivity improvement\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eCardiovascular risk factor reduction models\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eMetabolic syndrome intervention studies\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr\u003e\n\u003ch3\u003eEndocrine and Incretin Biology\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eDual incretin receptor synergy research\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eGut–pancreas–brain axis signaling\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eHormonal regulation of postprandial metabolism\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr\u003e\n\u003ch2\u003eTechnical Specifications\u003c\/h2\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProperty\u003c\/th\u003e\n\u003cth\u003eTirzepatide\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFunctional Class\u003c\/td\u003e\n\u003ctd\u003eDual GLP-1 \/ GIP receptor agonist\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeptide Length\u003c\/td\u003e\n\u003ctd\u003e39 amino acids\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMolecular Weight\u003c\/td\u003e\n\u003ctd\u003e~4,813 Da\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStructural Modification\u003c\/td\u003e\n\u003ctd\u003eFatty acid chain for albumin binding\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdministration (clinical use)\u003c\/td\u003e\n\u003ctd\u003eSubcutaneous injection\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHalf-life\u003c\/td\u003e\n\u003ctd\u003e~5 days (enables weekly dosing)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrimary Targets\u003c\/td\u003e\n\u003ctd\u003eGLP-1R and GIPR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMechanism Type\u003c\/td\u003e\n\u003ctd\u003eIncretin-based metabolic regulator\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003chr\u003e\n\u003ch2\u003eStability \u0026amp; Storage\u003c\/h2\u003e\n\u003ch3\u003eLyophilized \/ Unreconstituted Form\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eStore at \u003cstrong\u003e-20°C\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eProtect from light and moisture\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eAvoid repeated freeze-thaw cycles\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eMaintain sterile pharmaceutical-grade handling\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr\u003e\n\u003ch3\u003eReconstituted \/ Injectable Form\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eStore at \u003cstrong\u003e2–8°C (refrigerated)\u003c\/strong\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eLimited stability depending on formulation\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eUse within defined clinical or research timeframes\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eAvoid agitation and temperature fluctuations\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr\u003e\n\u003ch2\u003ePharmacokinetic Notes (Research Data)\u003c\/h2\u003e\n\u003cp\u003eIn clinical and experimental studies:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eLong half-life due to albumin binding modification\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eSteady-state achieved with weekly administration\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eSustained receptor activation across GLP-1 and GIP pathways\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eDose-dependent metabolic and appetite regulation effects\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr\u003e\n\u003ch2\u003eSafety and Physiological Considerations (Research Context)\u003c\/h2\u003e\n\u003cp\u003eObserved in clinical research:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eGastrointestinal side effects (dose-dependent)\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eAppetite suppression mediated via central pathways\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eImproved insulin sensitivity in metabolic populations\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eHormonal feedback remains glucose-dependent rather than constitutive\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr\u003e\n\u003ch2\u003eResearch Keywords \/ PubMed Search Terms\u003c\/h2\u003e\n\u003ch3\u003eCore Topics\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003etirzepatide GLP-1 GIP dual agonist\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eincretin receptor agonists metabolism\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eglucose-dependent insulin secretion peptide\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003ealbumin-bound peptide pharmacokinetics\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr\u003e\n\u003ch3\u003eMetabolic Research\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eobesity GLP-1 GIP weight loss\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003einsulin resistance incretin therapy\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eappetite regulation central nervous system incretins\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003ecardiometabolic risk reduction peptides\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr\u003e\n\u003ch3\u003eClinical Context\u003c\/h3\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eSURPASS clinical trials tirzepatide\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003etype 2 diabetes incretin dual agonist therapy\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003emetabolic syndrome incretin drugs\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr\u003e\n\u003ch2\u003eResearch Use \/ Context Disclaimer\u003c\/h2\u003e\n\u003cp\u003eThis material is intended for scientific and educational reference based on published literature and clinical research data.\u003c\/p\u003e\n\u003cp\u003eTirzepatide in approved formulations is a prescription medication in many jurisdictions and must be used only under appropriate medical supervision.\u003c\/p\u003e\n\u003cp\u003eThis description:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eIs not medical advice\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eIs not a dosing guide\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eIs not intended to promote unsupervised use\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eReflects research and clinical trial data only.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr\u003e\n\u003ch2\u003e\u003cspan\u003eScientific References\u003c\/span\u003e\u003c\/h2\u003e\n\u003col data-spread=\"true\" start=\"1\"\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2206038\"\u003e\u003cspan\u003eJastreboff AM et al. Tirzepatide research. New England Journal of Medicine.\u003c\/span\u003e\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/36908082\/\"\u003e\u003cspan\u003eFrias JP et al. Clinical investigations of Tirzepatide.\u003c\/span\u003e\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ol\u003e","brand":"NordBioLab","offers":[{"title":"10 MG","offer_id":57689567592780,"sku":null,"price":129.0,"currency_code":"EUR","in_stock":true},{"title":"30 MG","offer_id":57689567625548,"sku":null,"price":279.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1058\/8363\/1948\/files\/nordbiolab-tirzepatide-holographic-vial.png?v=1782719270"}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1058\/8363\/1948\/collections\/genrate-square-clean-lab-style-on-the-light-blue-background-picture-of-vial-with-lyophilized-powder-yopu-can-use-2d5a8c-color-also.png?v=1783118323","url":"https:\/\/nordbiolab.com\/collections\/glp-1-research-peptides.oembed","provider":"NORDBIOLAB","version":"1.0","type":"link"}